Philip Morris International Inc. (PM) Earnings Call Transcript & Summary

October 21, 2026

New York Stock Exchange US Consumer Staples Tobacco earnings 78 min

What were the key takeaways from Philip Morris International Inc.'s October 21, 2026 earnings call?

In the third quarter of 2026, Philip Morris International (PMI) reported strong financial results, with net revenues of $11.4 billion, reflecting a 7.1% organic growth year-over-year. Adjusted diluted EPS reached a record $2.36, up 6% excluding currency impacts. Management maintained its full-year guidance for organic net revenue growth of 5% to 7% and adjusted diluted EPS growth of 7.5% to 9.5%, signaling confidence despite rising cost pressures from geopolitical tensions and increased investments in the U.S. market.

What topics did Philip Morris International Inc. cover?

  • Strong Revenue Growth: PMI achieved organic net revenue growth of 7.1% in Q3, driven by robust pricing and a favorable category mix. Management stated, "We achieved plus 7% organic growth in Q3 net revenues and more than 10% growth in operating income."
  • Record EPS Performance: Adjusted diluted EPS reached a new high of $2.36, representing a 6% increase year-over-year. Management noted, "Our adjusted diluted EPS growth of plus 6%... to a record quarterly level of $2.36."
  • Geopolitical Cost Pressures: Management highlighted ongoing cost pressures due to geopolitical tensions, particularly in the Middle East and Ukraine, which are expected to impact profitability. They stated, "We guided you to a full year impact of 0.5 of EPS... due to disruptions in Ukraine."
  • U.S. Investment Strategy: PMI is significantly increasing its investments in the U.S. to support the ZYN brand, with Q3 SG&A expenses rising to $370 million and expected to increase by 10% in Q4. Management emphasized, "We are making this value optimization in terms of price adjustment... to build ZYN into the strongest smoke-free brand in the U.S."
  • IQOS Shipment Trends: IQOS HTU shipments reached 41.5 billion units in Q3, with year-to-date growth of 6.7%. Management indicated that they expect HTU shipment growth to be slightly below adjusted IMS growth for the full year, stating, "We now expect HTU shipment growth to be slightly below adjusted IMS growth for the full year."

What were Philip Morris International Inc.'s October 21, 2026 results?

  • Operating Income: $5 billion (Exceeds $5 billion for the first time)
  • Adjusted OI Margin: 45% (Reached close to 45%)
  • SG&A Expenses: $370 million
  • HTU Shipments: 41.5 billion units (Year-to-date growth of 6.7%)
  • Organic Net Revenue Growth Guidance: 5% to 7% (Maintained guidance)
  • Adjusted Diluted EPS Guidance: 7.5% to 9.5% (Maintained guidance)

PMI's strong Q3 results reflect solid operational performance and a commitment to growth, particularly in smoke-free products. However, rising geopolitical costs and increased U.S. investments pose risks to short-term profitability. Investors should monitor the impact of these factors on future earnings and the effectiveness of the company's strategic initiatives.

Earnings Call Speaker Segments

James Bushnell

executive
#1

Good day, and thanks for being here. We put out a press release earlier today with full details about how we performed in the 2026 third quarter. You can find that release on our site, pmi.com. There's a glossary of terms — it covers the definition of Smoke-Free Products — and it also includes adjustments, other calculations, and reconciliations to the most directly comparable U.S. GAAP measures for the non-GAAP financial measures we cite in this presentation; all of that sits in the exhibit to our Form 8-K dated today and on our Investor Relations website. Remarks today include forward-looking statements and projections of future results. Please turn your attention to the forward-looking and cautionary statements disclosure in today's presentation and press release, which reviews the various factors that could cause actual results to differ materially from projections or forward-looking statements. Massimo Andolina, Group Chief Financial Officer, is with me today. Massimo, over to you.

Massimo Andolina

executive
#2

Thanks, James, and hello everyone. We turned in excellent results for the third quarter. Our volume momentum carried on, which keeps us squarely on course for a sixth straight year of total shipment growth and, in 2026, yet another year of best-in-class results. The smoke-free business kept up its strong underlying momentum: IQOS HTU shipments landed at the high end of what we expected, and growth fundamentals accelerated across all three of our flagship brands. Alongside standout combustibles performance, that gave us +7% organic growth in Q3 net revenues and more than 10% growth in operating income, even with tough comparisons on smoke-free shipments and added cost pressures — notably from the ongoing conflicts in the Middle East and Ukraine. Q3 adjusted OI topped $5 billion for the first time, and our adjusted OI margin came in close to 45%. This strong operational performance underpinned better-than-expected adjusted diluted EPS growth of +6%, excluding currency, reaching a record quarterly level of $2.36. IQOS kept making strong, broad-based progress, with adjusted IMS volume growth rising to +7.1% in the quarter, or +10% excluding Japan and Poland, where we faced specific headwinds from the impact of excise-driven pricing and the characterizing flavor ban, respectively; in nicotine pouches, ZYN's Q3 shipment growth accelerated in international markets and reached +4% in the U.S., or +13%, excluding the special promotional activity of September 2025. Supporting this performance was the ongoing rollout of new variants, as we invest significantly in the accelerated expansion of our product offer and align the portfolio value proposition over the second half of this year; we are pleased with the initial consumer reaction and the sequential increase in category share, even though we have yet to reach full commercial deployment of the first wave of expansion. We remain focused on further strengthening the brand, building consumer awareness of the expanded portfolio, and continuing to invest behind the significant growth opportunity ahead. In E-Vapor, VEEV carried on its outstanding progress, with shipment growth stepping up to +62%. We delivered strong performance across key markets and continued to build our leading position in Europe, the primary international profit pool. Our combustible business put in a standout Q3 performance, beating our expectations through a combination of stable volumes, high single-digit pricing, and a specific benefit from the restructuring of distribution terms in certain markets. Volumes held up especially well in markets where smoke-free alternatives remain unavailable or have limited presence, while the continued strength of our brand portfolio, led by Marlboro, supported category share gains and further margin expansion. That aligns with our objective of maximizing combustible value over time to support the growth of our smoke-free business. Our overall year-to-date performance further demonstrates the sustainability of our growth model. We continue to expect another year of high-quality, best-in-class volume, sales, and profit growth as we keep investing behind our leading smoke-free platforms to drive long-term value. Turning now to our headline financials for the third quarter. We achieved shipment growth of +0.6%, beating a largely flat industry even though we faced tough comparisons on HTUs. Along with solid pricing and a favorable category mix, that fueled organic net revenue growth of +7.1%, or +5.5% in dollar terms, reaching $11.4 billion. Gross profit rose organically by over +8%, while adjusted operating income climbed +10.5% organically and +9.6% in dollar terms. This mirrors robust top-line expansion and efficient cost control, even as we stepped up growth investments, particularly in the U.S. Adjusted diluted EPS rose +5.4% to a fresh quarterly record of $2.36; that figure includes an unfavorable currency drag of $0.01 from dollar strength and smaller positive transactional effects than we had anticipated, largely because of the strengthening Russian ruble. As we noted last quarter, this growth also reflects a tough comparison against a low tax rate in the prior-year period, which cut Q3 EPS growth by roughly 4 percentage points. Our excellent year-to-date performance further shows the strength and quality of our business fundamentals, with shipment volume growth of +0.5%, strong pricing, and favorable category mix; that pushed organic net revenue growth to +5.9%, or +8.2% in dollar terms, lifting year-to-date net revenues to almost $33 billion. Adjusted gross profit rose +7.1% organically, while adjusted OI grew 7.7% organically and +10.6% in dollar terms, surpassing $14 billion. We posted adjusted diluted EPS of $6.52, which means growth of +8.4% excluding currency and +11.8% in dollar terms. On shipment volumes, we saw solid growth both in the third quarter and year-to-date. As in recent years, structural expansion of our smoke-free portfolio more than made up for combustible declines, and we remain firmly on track for our sixth consecutive year of growth. Smoke-free shipments rose +2.7% in the quarter, despite the strong prior-year comparison, and +6.4% year-to-date, powered by IQOS. We still expect high single-digit growth in smoke-free adjusted IMS volumes and shipments for the year, with shipments dependent on year-end inventory movements. IQOS HTU shipments hit 41.5 billion units in Q3, with year-to-date growth of +6.7%. We now anticipate HTU shipment growth slightly below adjusted IMS growth for the full year, with Q3's pattern of adjusted IMS outpacing shipments continuing in Q4, chiefly because of the in-year phasing impact of price changes in Japan. Q3 shipment growth drew support from a broad set of markets, among them Germany, Greece, Spain, Indonesia, the U.K., the Netherlands, and global travel retail, each of which posted strong double-digit gains. Oral smoke-free volumes rose +1.8% in the quarter, helped by our readiness and capacity to launch new product variants in the U.S., together with faster international ZYN growth and share gains in Swedish snus. E-Vapor shipments jumped +62%, showing the growing scale and importance of our multi-category portfolio and VEEV's place in it. Cigarette shipments held flat in the quarter despite strong pricing, beating an industry decline of 1.1%. That speaks to how strong our brands are and how resilient the category has proven in places where smoke-free products are prohibited or only have a limited presence, including Turkey, Indonesia, and Egypt. Looking at the year to date, cigarette volumes are down 1.2%. The markets behind this better-than-expected result create an unfavorable geographic mix, yet because our combustible portfolio keeps holding up, we now anticipate that full-year cigarette volumes will be lower by roughly the same amount, depending on year-end inventory movements. We keep delivering strong top-line growth through the core pillars of our business model — namely volume growth, pricing power, and the mixed benefits of smoke-free unit economics. So far this year, pricing has remained the biggest contributor, adding +6.2 points of growth. That mirrors sustained combustible strength, with pricing at +9.1%, plus a positive contribution from our smoke-free portfolio, which includes low single-digit pricing on IQOS HTUs. A larger contribution from smoke-free products in our international business delivered another +1.5, I repeat, +1.5 points of growth. That holds notwithstanding a smaller impact in Q3 stemming from timing factors. Partly offsetting this was a 0.6 point headwind from the U.S., caused mainly by lower ZYN shipment volumes and tough comparisons earlier in the year; those headwinds eased considerably in the third quarter.

Massimo Andolina

executive
#3

Unpredictable market conditions, along with several other elements, reduced our growth by 1.7 points. Earlier I referred to changes we made to some distribution agreements, and those provided a partial counterbalance to these headwinds during Q3—though we anticipate little impact from them in Q4. As a result, organic net revenue growth reached +5.9% for the year to date, with Q3 alone at +7.1%. Foreign exchange contributed an additional +2.3 percentage points over the year-to-date period, lifting reported net revenue growth to +8.2%. Looking lower on the P&L, our adjusted operating margin rose organically by +60 basis points year to date and by +130 basis points in Q3, reaching an exceptionally robust level of nearly 45% for the quarter. Margin growth remained the biggest factor, contributing +80 basis points for both Q3 and year to date. That came from solid pricing, a helpful smoke-free mix, expanding scale advantages in our smoke-free operations, and better manufacturing productivity. Meanwhile, we continue putting substantial resources into future growth opportunities. In Q3, organic SG&A growth trailed net revenues, though this mirrors the continuing payoff from our G&A productivity efforts and a favorable year-over-year comparison that had included certain combustible-related items. Commercial spending on international and U.S. smoke-free both continued rising faster than the top line, with the pace picking up from the second quarter. Looking at the whole year, we anticipate SG&A growth will roughly track net revenues, since we're continuing to focus on back-office expenses while significantly ramping up commercial spending behind our growth platforms and consumer-facing initiatives worldwide. This includes greater investment in the U.S. to back the expansion and competitiveness of our ZYN portfolio. Our productivity program, in fact, continues to produce strong results; across both cost of goods sold and SG&A, we've now delivered over $2 billion in cumulative gross cost savings since 2024, meeting our three-year target ahead of schedule. Now turning to our international business, which continues to serve as the main driver of group performance and represents 93% of our net revenues year-to-date. For the international smoke-free segment, results so far this year have been outstanding: organic net revenues rose close to 10% and gross profit climbed 12%, which pushed gross margin up 120 basis points to 70%. That performance mirrors IQOS's ongoing expansion and improving profitability, along with added gains from our broadening smoke-free lineup, especially VEEV. Q3 growth, as anticipated, came in slower because of shipment timing comparisons and the associated category mix. Notably, IQOS gross margins kept widening substantially even with extra cost disruption in Ukraine. Our international combustible unit likewise posted a robust year-to-date showing. Gains in category share, solid pricing, and disciplined execution produced organic net revenue growth of 5.2% and gross profit growth of 7.4%, underpinning organic gross margin expansion of 140 basis points. Altogether, our smoke-free and combustible operations outside the U.S. produced organic net revenue growth of +7% and gross profit growth of +9.1%, while gross margin widened by +140 basis points to 68.8%. That result supported international organic OCI growth of roughly +11% in Q3 and also year-to-date, which sits comfortably above the targeted OI growth rates for total PMI. Moving to international smoke-free, total adjusted IMS year-to-date grew +8.6%, including an acceleration to +8% in Q3, even with the effects from Japan and Poland. Excluding those two markets, year-to-date growth reached +11.8%, consistent with the strong growth rates we have posted in recent years. What's key here is that our smoke-free business continues to expand about one percentage point faster than the comparable industry, and our share now stands at 62%, showing the increasing strength of our multi-category approach. I'd add that, for the first time, our international share of cigarettes and HTUs exceeded 30% during the quarter, highlighting the combined power of our smoke-free and combustible portfolios. IQOS continues to power our smoke-free expansion. Adjusted IMS volume growth climbed from +5.1% in Q2 to +7.1% in the third quarter; we're particularly happy with the +7.7% growth delivered year-to-date, notwithstanding the well-known headwinds in Japan and Poland. If we exclude those two markets, adjusted IMS growth was roughly +10% for the quarter and nearly +11% for the year to date, which matches the business's strong underlying momentum and the staying power of demand throughout our geographic footprint. Several key European countries — Italy, Greece, and Spain — each posted double-digit adjusted IMS growth year to date, and they were joined by excellent results in markets including Indonesia, Mexico, the Philippines, Saudi Arabia, and Taiwan, plus global travel retail, all of which underscores how our IQOS business is becoming more geographically diversified. Our pipeline across devices and consumables stays active, helping us both acquire legal-age consumers and build brand loyalty. We keep enhancing our premium TEREA and LEVIA HTU range with fresh taste experiences. The mainstream-priced versions of DELIA and SENTIA are likewise driving customer acquisition and are bigger than the nearest competitor in our category. Beyond that, we continue rolling out BONDS by IQOS, our alternative heating technology, and in the first launch markets it is landing well with entrenched smokers who are harder to reach. IQOS's strength shows in the outstanding offtake share gains in key cities worldwide, which is a solid signal of the growth potential at the national level. In Q3 we posted additional robust share gains across mature IQOS markets — Germany, Greece, Italy, Japan, Romania, the Netherlands, and the United Kingdom — as well as in global travel retail. We're still seeing quite encouraging traction in newer growth markets like Mexico, Indonesia, and Taiwan, where IQOS pushed its national category share above 80%. Turning to VEEV, which is still performing very strongly, shipment volumes for the year to date rose 68% to 4.0 billion equivalent units. That reflects ongoing gains and growing category leadership throughout European markets, as VEEV widened its lead over established competitors and held its position as the region's top closed pod brand. In other places, we're still seeing encouraging growth in markets including Egypt, Malaysia, global travel retail, and South Korea after its recent launch. Our company keeps gaining from a distinctive approach that spans multiple product categories, powered by IQOS's unmatched commercial setup and consumer footprint, and it also gains from the broad structural move toward closed pod systems in markets worldwide. That direction fits our portfolio and our commercial plan, since we are pushing momentum through meaningful innovation — for example, the ongoing launch of our attractive new VEEV ONE PLUS device, shown here on the slide. Turning to ZYN, it keeps delivering encouraging growth internationally as we put investment behind building the category. International shipment volumes so far this year hit 1.5 billion pouches, a rise of +6.3% on a like-for-like basis. That number reflects a +7% sequential gain in Q3, supported by improved quarter-over-quarter trends in Sweden following our release of new ZYN flavor variants. Strong double-digit increases continued across markets such as Poland, global travel retail, and Mexico, though these were partly offset by inventory shifts in the United Kingdom and Pakistan. The expansion was driven by portfolio innovation including ZYN Black Menthol, continued category growth, and greater consumer uptake across many markets. ZYN's ex-Nordics IMS growth for the year to date reached +30%, outpacing the industry and exceeding shipments. In Europe, our most advanced multi-category region, combined smoke-free IMS volumes for IQOS, ZYN, and VEEV climbed approximately +8.6% year-to-date and +8.9% in Q3, demonstrating strong momentum.

Massimo Andolina

executive
#4

IQOS adjusted IMS growth accelerated to +6% during Q3, and a notable driver was faster momentum in Germany and Spain. Results were solid throughout the region, with robust gains persisting in Italy, Greece, the United Kingdom, and Bulgaria, which more than compensated for disruption in Ukraine. If you set aside the headwinds in Poland stemming from the characterizing flavor ban that took effect earlier this year, adjusted IMS growth across Europe came in at roughly +8%. Our remaining smoke-free segments keep expanding quickly. VEEV shipment volumes rose +75% year-to-date and +66% in Q3, with exceptional growth in Romania, Greece, Germany, France, Bulgaria, and Spain. ZYN volumes hit 1 billion pouches year-to-date, accelerating to nearly +6% growth in Q3 on a like-for-like basis as we put investment behind the category; this was backed by solid progress in markets including Poland, Austria, and Finland, along with the improved Swedish delivery; in Japan, IQOS fundamentals stay strong amid volatility from the two-step excise increase on heated tobacco this year. After a Q2 decline in adjusted IMS volumes caused by pantry de-loading, HTUs came back to growth in Q3, rising +3.4%. Just as in Q1, prior to the April excise-driven price increase of JPY 40 per pack, Q3 IMS growth carries a favorable effect from consumer pantry loading ahead of our JPY 20 increase in October. Strip out that effect and underlying growth was +1.3%, as consumers steadily adapt to higher prices in a setting where combustible cigarettes had not yet encountered any excise change. That is still consistent with what we expected, and we continue to anticipate growth for the year, even with a likely softer Q4 as pantry loading once more reverses and consumers adjust to another price increase. Our adjusted heat-not-burn category share held steady at about 68%, even after we took more pricing than competitors in April, which underscores the strength of the IQOS proposition. Looking ahead, the excise calendar over the next three years appears less disruptive, with moderate increases on both combustibles and heated tobacco-like each April. Although the April 2027 increase will be the third change in 12 months, with a possible cumulative effect on the consumer, we remain enthusiastic about the category's midterm growth potential in Japan. Even though heated tobacco still represents more than 50% of total nicotine offtake, a substantial pool of smokers has yet to switch, which supports our confidence in the capacity for strong IQOS performance in the years ahead. Moving now to the U.S., where we posted strong financial performance in Q3, backed by ZYN volume growth of +4.2% to 3.2 billion pouches, or +13%, excluding the effect of one-off promotions in September last year. Versus Q2, shipments rose 10% sequentially, reflecting category expansion and the ongoing rollout of new portfolio variants, which have helped improve our category share and should position us well for future growth. For Q4, we anticipate shipment volumes will be roughly flat to slightly higher than Q3 as distribution keeps growing and we back the launch of the improved lineup. U.S. net revenues rose by nearly 23%, and gross profit went up +24%, while gross margins organically expanded by +60 basis points, reaching 64.4%. Favorable pricing comparisons versus the promotions in the same period last year drove this, even with greater manufacturing overheads and startup costs at our new ZYN facility in Colorado, where production is steadily ramping. Adjusted operating company income climbed +1.5% as we substantially raised commercial investments to back the growth of our ZYN portfolio. Thanks to our preparedness and capacity to bring new products to market, we are undertaking meaningful steps throughout the second half of this year to reinforce ZYN's competitive standing as the top premium U.S. smoke-free brand. Our first step is broadening the ZYN lineup through two waves, aimed at serving a wider variety of preferences among legal-age nicotine consumers. Wave one consists of the higher nicotine moist range, ZYN Ultra, plus a wider flavor selection for our flagship dry portfolio, and both are nearing full distribution. Although we are still raising consumer awareness of the new range, particularly ZYN Ultra, the early consumer response has been encouraging. In fact, after multiple quarters of volume gains trailing the category's growth rate, ZYN's category offtake share rose by an estimated 1.4 points between June and September, which shows the added contribution from the new variants and interest coming from competitor pouch users. We also started shipping wave two of product launches during the quarter, adding new flagship variants at 1.5 mg and 8 mg strengths, which widens the consumer offer further and advances our goal of persuading legal-age nicotine users to move into the category. Our second key step is harmonizing the value proposition throughout the portfolio and refining ZYN's per-pouch price positioning. That process started over the summer when we launched ZYN Ultra in 20 pouch cans, and beginning in October we are moving our 1.5 mg, 3 mg, and 6 mg flagship variants from 15 to 20 pouches; these variants account for a large majority of our volumes, and as we strive to carry out the change smoothly for consumers and trade partners alike, we expect it to be largely finished in the fourth quarter. As we noted at Q2 earnings and in later communications, these steps come with a requirement to increase investments. Total U.S. segment SG&A rose considerably to roughly $370 million in Q3, and we anticipate another exceptional sequential rise of about 10% in Q4; that mirrors greater consumer communication aimed at building awareness of the expected portfolio and strengthening the value proposition, along with the ramp-up of our When It Clicks brand campaign. Beyond Q4, we consider the Q3 spending level adequate to support the brand. Moving the 20-pouch cans forward is a major commitment to giving consumers more value, and if nothing else changes, that works out to roughly 25% lower revenue for each pouch. Add to that the extra near-term backing we're putting behind the current 15-pouch variants so they sell through cleanly at retail, and Q4 net revenues will take a hit. In fact, when you add up the combined effect of these steps plus the build-out of our manufacturing capacity to fuel future growth, Q4 stands out as an unusual quarter defined by investment. We're anticipating an unusually weak level of U.S. profitability in the fourth quarter, with adjusted OCI landing near zero or a bit below it. Our top global position and robust growth trajectory come from sustained investment aimed at medium- and long-term expansion, and we're thrilled to be rolling out these substantial enhancements to what ZYN offers consumers. Given a rapidly expanding category and ZYN's leading brand equity, we think we're setting the brand up for powerful, lasting growth in the years ahead. Lastly, on combustibles, which delivered an outstanding Q3. Pricing continued to power results, hitting +8.9% in the third quarter and +9.1% year-to-date, with widespread gains across markets such as Turkey, the Philippines, Indonesia, and Poland. We now anticipate full-year pricing above 8%, with the net revenue effect partly offset by a less favorable geographic mix.

Massimo Andolina

executive
#5

Despite that healthy pricing, our portfolio-wide international category share climbed 0.4 points in Q3 to 25.9%, driven by Marlboro reaching a record peak of 11.4%. Alongside that robust pricing, the share gain delivered another quarter of outstanding profitability, as international combustible gross profit rose +9.8% in Q3 and +7.4% year-to-date. Turning to the full-year outlook, we're targeting a second straight year of double-digit adjusted diluted EPS growth in dollar terms. Following a strong first nine months, we remain on course for another excellent year as we continue investing behind smoke-free growth. We now anticipate that overall shipment volumes will increase this year, and if that happens, 2026 would mark our sixth straight year of growth. For net revenues, we're still projecting organic growth of +5% to +7%. Given how strongly we've delivered so far this year and our expectation that international smoke-free will drive a robust fourth quarter, we believe the business could finish in the middle or upper half of that range. On operating income, we continue to expect organic growth of 7%-9%, which reflects strong inherent margin expansion stemming from our top-line performance and productivities—and that holds even with the substantial ongoing investment we're making in SAP internationally and in the U.S. Our forecast range for currency neutral adjusted diluted EPS growth also remains at 7.5%-9.5%. Taking into account an approximately $0.18 tailwind from currency at prevailing exchange rates—driven in particular by the recent softness in the euro—we arrive at an adjusted diluted EPS range of $8.29 to $8.44, which equates to roughly +10% to +12% growth in dollar terms. That said, because of the substantial second-half ramp in U.S. investments and the cost pressure stemming from ongoing geopolitical tensions, we view full-year delivery as more probable toward the midpoint or the lower half of both brackets. While the inflation picture is still uncertain—above all the persistence of energy-related inflation tied to the conflict in the Middle East—pricing for certain inputs has started to reflect higher energy and shipping costs. Although our exposure is lower than that of numerous other consumer goods segments and the situation stays controllable on the whole, these elements acted as a drag during Q3 and should keep shifting in Q4 as a bigger share of higher input costs passes through. All told, we figure the effect on full-year adjusted diluted EPS growth at roughly half a percentage point, plus a comparable headwind stemming from Ukraine disruptions. That gives us a total impact of about one point of growth for the year. Looking at Q4 in general, we expect our international business to deliver solid net revenue and OCI results, with smoke-free performance picking up speed again. We're looking for adjusted IMS to keep growing solidly, with HTU shipments in the range of 39.5 billion to 40.5 billion units, which lines up with what we said about how shipments are phased; on the other hand, as I explained, the U.S. will see an unusual quarter marked by heavier investment and portfolio transition. Despite that unusual quarter in the U.S., we still expect strong overall delivery from the group, and that's what our full-year outlook captures. We also expect to generate operating cash flow of about $13.5 billion — a record — which shows how effectively we turn business into cash. That leaves us ample room to fund future growth while continuing to cut debt and continuing to give shareholders attractive value. Let me wrap up now with a few main points. What we've done so far this year shows the quality of our underlying fundamentals and puts us in position for yet another year of superior growth on both the top and bottom lines, as we keep investing heavily in the opportunities ahead. It comes down to how durable our model is, backed by category-leading brands, real pricing strength, careful cost control, and the growing scale of IQOS, ZYN, and VEEV. We stay a business that throws off a lot of cash, firmly committed to our progressive dividend policy and to rewarding shareholders. In September we lifted our dividend for a 19th year in a row, to $6.40 per share, an increase of almost 9%. Going forward, we're confident about our mid- and long-term path, which mirrors the distinctive strengths of PMI's growth model. There's structural smoke-free momentum rooted in science, innovation, commercial strength, and brand building, paired with combustible resilience and smart reinvestment. We look forward to saying more about all of this at our next Investor Day, which we're planning for Q2 next year. Many thanks for listening, and we're now glad to take your questions.

Bonnie Herzog

analyst
#6

Okay, thanks. Hi there—how are you? My first question, I guess, is about your guidance. Q3 actually came in above your guidance for the quarter on both the top line and EPS. And yet, as you mentioned, you're now pointing to the middle or the lower half of the full-year organic OI growth guidance, and it sounds the same way on your EPS growth guidance. I know you cited the greater cost pressures stemming from ongoing geopolitical tensions, but I really wanted to confirm whether you're also now planning to spend more in the U.S. For instance, are you finding that implementing some of the strategic initiatives you've highlighted now costs you more—like putting 20 pouches in all ZYN cans? How should we think about those higher costs and that spending in the U.S. in terms of your profitability and EPS growth next year?

Massimo Andolina

executive
#7

Thanks so much, Bonnie. Good to hear from you. You're right. For the full year, our guidance for OI and for EPS points toward the mid or lower half of the range. As you could read, the main element in there is—well, there are fundamentally two main elements. One is the cost pressure coming from geopolitical factors. That cost pressure has been building through the year, and we begin feeling its impact more during Q3 and Q4. We guided you to a full-year impact of half a point of EPS. You could read from that, therefore, that the flow-in is mostly in H2; we guided you to another half a point coming from disruptions, which are kind of one-off things that have happened in Ukraine owing to, sadly, three events of bombing of some of our supply chain facilities, and therefore destruction of goods. Frankly, if you look at that and you look at our guidance, that adds up to one point, and it means that just that one—had we not had those impacts, we would be in the mid to higher half of the range. The other important element in the quarter, and especially in Q4, is the exceptional level of investment we are making in the U.S. I assume you will all acknowledge that the investment we are making in the U.S. across Q3 and Q4 is exceptional, by all means. I would point you to a couple of elements in that. First and foremost, the fact that we are moving our flagship portfolio to an optimized premium price positioning, which de facto means a better value proposition for consumers, and in practical terms, it means a 25% price reduction on a per pouch basis—a 1 for 1.5 million shift, as we migrate our entire flagship portfolio from 15 to 20 count at the price of the 15 counts. As you can imagine, that by itself affects the revenue line. During a transition phase across Q4, we'll pair that with commercial activities at the retail level—activities that hit the revenue line—to help ease the sellout of the remaining 15 count cans in the market. The third thing we're doing is a special investment that's already coming in during Q3, and we told you there could be a special bump in Q4 of 10% compared with the Q3 impact; we said about $370 million in Q3 and a special 10% rise in Q4, so a few things remain possible for us. First, we keep growing ZYN into the top smoke-free brand in the U.S. Second, we've nearly tripled how many nicotine pouch variants we offer across the year, and we're pursuing this value optimization through price adjustment. So we want to dial up branding communication via the When It Clicks campaigns and keep that expansion going. Meanwhile, there's something really important we want to do: keep raising consumer awareness that these new variants exist, plus awareness of the product's new price. All of these should be read as things that will be ramped up further in Q4 compared with Q3. Yet, as the guidance stated, you could take the Q3 cost level as a solid proxy for commercial investment across next year. So, bringing it all together, Bonnie, honestly, I find strength in the bottom-line and EPS guidance we're providing, since we're shifting it to the middle and lower half of the range purely to correct for the cost I described earlier; effectively we are absorbing nearly all of the heavy U.S. investments we're making, backed by strength everywhere else in the business. Said differently, without those inflationary pressures—which we've experienced far less than what other FMCG companies' disclosures show in the regions, at a far more manageable level than many others have—without them, we'd in fact sit at the middle to upper end of the range. I trust that answers your questions.

Bonnie Herzog

analyst
#8

No, absolutely — that was useful. Just so I'm clear, Massimo: when I think about next year, the spending levels in the U.S. this year, I'm thinking about that carrying on next year. Did I get that right?

Massimo Andolina

executive
#9

I think what we-

Bonnie Herzog

analyst
#10

Perhaps even more than that

Massimo Andolina

executive
#11

What we're steering toward is the reality that the spending figure you're observing in Q3 serves as a solid stand-in for the run rate we'll carry into next year.

Bonnie Herzog

analyst
#12

Got it. That makes sense.

Massimo Andolina

executive
#13

For Q3, keep in mind there’s one more factor—a greater expense tied to the fact that our Colorado facility has only just come online. Loading at that plant remains low, so the overheads there weigh on results. Next year you’ll see a cost level for which Q3 serves as a solid proxy, and clearly we’re counting on the category’s growth in the year ahead, and we take encouragement from the share results observed from June through now.

Bonnie Herzog

analyst
#14

All right, and perhaps a few brief follow-ups regarding ZYN, since you brought it up. I'd be interested to hear, in your view, how the recent ZYN innovations you've launched are doing against your own internal expectations, and ultimately, how much incremental benefit do you believe those innovations will bring to flagship ZYN? Then second, about the shift to 20 pouches per ZYN can, I'm wondering how you expect that to affect consumer behavior, if it does at all. For example, do you view it — I don't know — as a drag on volumes, or might it actually be a boost if consumers now use more because there are more pouches in every can they purchase? Just trying to reason through it. Thank you.

Massimo Andolina

executive
#15

All right, we're quite thrilled about the early results from both the flavor expansion across our flagship dry lineup and the launch of the higher nicotine strengths, 9 mg and 11 mg, within our Ultra lineup. I have to say that the response we've received from consumers — and a couple of weeks ago I had the chance to be in the U.S. and dig deeply into this — has been overwhelmingly favorable. That covers existing ZYN users who had genuinely been eager for additional flavor choices at the 3 mg or 6 mg strengths they were accustomed to. Reactions to those dry flavors have been truly excellent; it also covers consumers who had questioned why ZYN offered no higher nicotine option, and who might otherwise have looked at the competition. Honestly, in the data we've reviewed from our consumer research, we find strong interest in what we've introduced. We've observed an influx both of legal-age smokers entering the category and of rivals' users — and, in the case of 9 mg and 11 mg, of people who had abandoned ZYN for competitors' higher-nicotine offerings and who have now returned to ZYN because of those launches. We see all of that reflected in share. As you can observe, share has been positive since June and since these launches began. So I can only expect that, with the price premium adjustment at this point, we ought to see still greater competitiveness and more momentum ahead. As for your question about consumer behavior — well, Bonnie, let's wait and see. I can share my own experience: when I have more in my pocket, I tend to use more.

Bonnie Herzog

analyst
#16

Yeah.

Massimo Andolina

executive
#17

That's something I notice with my kids whenever they're shopping.

Bonnie Herzog

analyst
#18

Yeah.

Massimo Andolina

executive
#19

Juices and other things.

Bonnie Herzog

analyst
#20

Yeah.

Massimo Andolina

executive
#21

What's sitting in your fridge in greater quantity is what you'll reach for more often.

Bonnie Herzog

analyst
#22

Yeah.

Massimo Andolina

executive
#23

It's fair to assume that will hold true. One point I'd like to address, though, drawing on what I've seen internationally: when consumers enter the category and grow accustomed to it, and they remain in the category, two developments emerge. Nicotine levels tend to rise somewhat, and as people stay in the category, their average daily consumption also tends to climb. One could say that in the U.S. today, where the category is still at its outset, average daily consumption is likely in the low single digits. In markets where the category has existed for a longer period, you actually observe daily consumption closer to the high single digits. That gives us yet another driver of category growth to anticipate.

Bonnie Herzog

analyst
#24

All right, wonderful. Thanks for sharing everything. I'll make sure that gets passed along.

Massimo Andolina

executive
#25

Thanks so much, Bonnie.

Matt Smith

analyst
#26

Hello, and thanks for taking my question. I'd like to build on what you said about inflation and its effects. You mentioned a half a point of EPS drag for the year, with some impact in Q3 and more in Q4. If we look at just the fourth quarter alone, should we think of that as more than a one-point hit to profit, and how do you see the levers for offsetting that going forward? You hit your cost savings target early and pricing has been above historical levels, but how do you view both of those now looking ahead? Thank you.

Massimo Andolina

executive
#27

Thank you, Matt. Well, let me start by saying one thing. This is a highly volatile situation, and the inflation is stemming from it, because it originates mainly in a geopolitical conflict in the Middle East that is pushing energy prices higher and, as a result, a range of inputs and services. As we've shown before, our supply chain has a certain resilience. In fact, even though the conflict has also persisted through the first half of the year, we are only now seeing these cost elements flow more meaningfully into our P&L during the second half. I won't give you guidance, Matt, on exactly how those elements split across the different quarters. Q4 is likely the quarter where we feel it most, simply from a timing standpoint, since those higher-priced inputs are arriving now. What I can tell you is that we've been through this before. You might recall the early days of the war in Ukraine, and we have repeatedly shown how resilient our model is and how capable we are of mitigating those costs. Frankly, you're seeing that again right now, because if you compare the half a point we're guiding for this year with what many of our other peer companies operating in the region are guiding, you see much bigger impacts from it. That's a testament to the resilience of our supply chain and to the fact that we have a broadly sourced set of materials coming from all over the world, plus contracts that protect us over a period of time and will let us navigate this. That said, none of those protections can last indefinitely. The situation is highly volatile; just as it's affecting us now, it could vanish the moment conditions on the ground return to normal. On your last point, look, we've demonstrated this year and in prior years that our pricing power is very strong, and we're entering 2027 with what is probably a super strong P&L at this point, and balance sheet as well, by the way, with margins expanding at the gross level and at the operating income level. As you've seen, through the year to date we've widened gross margin by 80 points and operating margin by 60 points; we're heading into 2027 from a position of strength, which leaves us very well placed to handle those effects if that does indeed go ahead.

Matt Smith

analyst
#28

Thanks for that. May I ask a follow-up? Your guidance shifted somewhat for heated tobacco IQOS shipment growth compared with in-market sales growth. As I understand it, you now expect shipments to lag IMS slightly. Could you elaborate on that gap and share how you see inventory levels as you head out of 2026? Are they at a normal level, or does this gap give you a chance to catch up further going forward? Thank you.

Massimo Andolina

executive
#29

Thanks for the question, Matt. Look, we have to acknowledge that 2026 has been somewhat unusual for heat-not-burn, in that one event in particular has stood out. There has been this taxation, and the resulting tax-driven pricing in Japan, not once but twice. So a range of preparatory steps for that unprecedented event took place, both last year—when, at the end of the year, shipments were higher—precisely so we could prepare for the pantry loading that comes from consumers who aren't accustomed to that magnitude of price change, both at the retailer level and at the consumer level. You saw a phasing of shipments in which we had considerably higher shipments in the first half of the year, in H1, and lower shipments in H2. From what we just showed, you saw that the IMS trend likewise reflects the pantry loading in Japan. Since our April pricing was JPY 40, but our October pricing is JPY 20, we are obviously seeing less pantry loading from consumers given the smaller increase occurring in the second half of the year, as we saw in the first half. That means we entered well-equipped from a shipment standpoint, and so with that phasing of shipments, IMS will run slightly ahead of shipments, and as a result you will see inventories coming down—but always at a very healthy level—and so we also capture the benefit on the working capital side.

Matt Smith

analyst
#30

Thanks — I'll be sure to share that.

Massimo Andolina

executive
#31

Thanks, Matt.

Eric Serotta

analyst
#32

Great, and thanks for taking the question — and thanks, Massimo. First, could you talk a bit about the puts and takes for international smoke-free growth next year? I realize you're not going to give us guidance today. But clearly 2026 was an extraordinary year. You talked about a less unfavorable or more normal tax environment in Japan next year. You'll be cycling the flavor ban in Poland. Any other big considerations to keep in mind as we start to think about international smoke-free IQOS next year? I know there are tax changes in Germany, much smaller than Japan, but I believe they impact HTUs. But is there anything else, more broadly, regarding the pluses and minuses for IQOS internationally next year?

Massimo Andolina

executive
#33

Eric, many thanks for that question. Well, look, I won't be giving guidance for next year; that's something we'll discuss in February. As you mentioned, pluses and minuses — I'll share my views on this. The first view I'd offer is that, if you examine how our IQOS performed throughout the year, we have shown strong momentum in terms of IQOS IMS. What I would point out here is that the geographic base across which that growth has spread is growing broader and broader. We showed adjusted IMS growth of 7.7% for the year to date. Strip out what happened in Japan and Poland, and IMS growth comes to 10.8%. Set that beside 2025, when the figure was 10.6%, and you can see the momentum exists and is in fact building. That rise also reflects a growing number of markets posting double-digit IMS growth, and sizable ones at that. Right now the double-digit group includes Italy, Greece, Spain, the Netherlands, the United Kingdom, and Germany. A lot of these markets weren't on the list before—they're places we began putting money into a few years back, and now the results are showing up. Indonesia is growing very well, and so are Mexico, Saudi, and Taiwan, where we've taken over 80% of the share in the category. GTR, Global Travel Retail, keeps adding positively. From an IMS standpoint, once you strip out those one-time events in Japan and Poland, the momentum is there, and the fact that growth is spread across different geographies gives me confidence that it will hold up. This year's Japan situation was somewhat unusual, I'd say, since you've got an asymmetric setup where just one category absorbs a fairly significant tax and price hike. If you look at the increases we had to put through on IQOS consumables alone, you're dealing with a Japanese consumer who isn't used to seeing prices go up — over 10% in one year, while cigarettes didn't move. Going into the following year, with a JPY 12 increase applying across the board to both HTUs and cigarettes, you could describe that as a more gradual increase, one that creates a smaller shock for the category as a whole. Another point I'd invite you to keep in mind is that we've now introduced our new offering, namely BONDS and BLENDS, across a range of markets, including, incidentally, certain prefectures here in Japan. You'll recall that one of the things we genuinely wanted to solve — particularly in a country like Japan, where penetration of the category among nicotine users exceeds 50% — concerns those who remain entrenched and have not yet switched: what kind of proposition might actually prompt them to make the move? That's where we stand now with BONDS and BLENDS across a number of markets. The proposition is performing well, and consumer feedback indicates it achieves precisely what we intended — it succeeds in persuading entrenched smokers to switch, since in BONDS and BLENDS they find the closer-to-cigarette experience they've been seeking. As a result, we observe fewer HTU users transitioning to BONDS and BLENDS. Their reaction is, "Hmm, too strong for me," yet more smokers are migrating there, which means it's functioning just the way we want. We're only at the start of that journey. I can't help but feel encouraged by what I'm witnessing. One final remark, though my answer has already run long: we're also beginning to see some new markets open. Taiwan became accessible last year, and the speed of our progress there is clear—the business has grown strongly and we've become unmistakably the category leader, ahead of the traditional leader in the CC business in that market. More recently, regulatory changes have emerged in Argentina, a positive move toward being able to enter the Argentine market next year as well. That means additional markets may join; whether they will join isn't the question. It's more a matter of when. So our confidence in the HNB trajectory remains extremely strong, Eric.

Eric Serotta

analyst
#34

Thanks, that was very comprehensive and genuinely helpful. If I could just ask one brief follow-up. As I understand it, price has never been the main driver behind IQOS expansion—growth comes largely from increasing penetration. It does appear that the price mix, or the implied price mix, within international smoke-free came in a bit softer this quarter. I believe it was around 3.5% in the first half, and closer to—by my math, 70 basis points in the third quarter. I'm just curious about what's driving that. Is it purely last year's comparisons? Is it partly geographic mix? Is it product mix involving BONDS by IQOS? What exactly happened during the quarter, and how should we think about price mix for international smoke-free going forward?

Massimo Andolina

executive
#35

That's a great question, Eric. Regarding how much IQOS revenue grew this quarter, there are a couple of points I want to raise. Two things to keep in mind. First, the year-over-year shipment comparison is clearly having an effect. You saw that our total SFP shipment volume grew 2.7%, a lower growth rate than what you've observed in earlier quarters. Obviously, since IQOS makes up such a large portion of our smoke-free portfolio, it's the IQOS shipment volume comparison that's really dragging that figure down, because you've seen excellent growth in the other two categories. There's a second element to consider. So within that, there's a category mix effect once you translate it into revenues. And a third factor: some pricing choices—specifically when those pricing moves landed, particularly on IQOS—were made and did affect the quarter. That's the whole of it; nothing else in that regard worries us at all.

Eric Serotta

analyst
#36

Excellent — I really appreciate that, and I'll make sure to share it.

Massimo Andolina

executive
#37

Thanks a lot, Eric.

Pallav Mittal

analyst
#38

Morning, and thanks for taking my question. First, on ZYN and Ultra: obviously, there's been some worry about how volumes have picked up over the past couple of months. U.S. EBIT this quarter is up just 1.5% against a very easy comp, and for Q4 you're saying it'll be flat to slightly down. Since those investments will carry on into next year, is it reasonable to expect U.S. EBIT to fall next year?

Massimo Andolina

executive
#39

The U.S.?

Pallav Mittal

analyst
#40

The EBIT-

Massimo Andolina

executive
#41

Can you repeat the last?

Pallav Mittal

analyst
#42

So in the U.S., EBIT would go down next year?

James Bushnell

executive
#43

Pallav, I apologize — your line isn't coming through clearly, but what I believe you're asking about is next year's U.S. EBIT.

Massimo Andolina

executive
#44

Okay, so regarding next year — as I mentioned earlier, I won't be giving guidance for next year at this point. What I can do is offer some considerations so you can form your own conclusions. You've observed that our nicotine pouch volumes have now increased quarter-on-quarter across the last three quarters, and we provided guidance on how Q4 would perform. You're aware that we're confident about the category going forward, and we stated it will see strong double-digit growth ahead; and you've seen how our share has performed. Frankly, we also gave guidance — and I covered this in Bonnie's earlier question — on the cost level to expect for next year, and that taking Q3 as a solid proxy for next year's run rate makes sense. So you can assume that, with volume growth continuing from the category and from our capacity to hold or even grow share, the absorption of those costs will improve, including the investments we've made in Colorado for the manufacturing facility. From that, you can work out what the likely trajectory for EBIT will be. One point to bear in mind is that, obviously, the 25% price optimization we're implementing in Q4 will have a lagging effect on the revenue level for three quarters, though on growing volume. That's what I'd keep in mind, and then we can give better guidance when we speak again in February.

James Bushnell

executive
#45

Pallav, we can barely hear you — the connection is really bad — so unfortunately we’ll need to go on to the following question. If you have anything you’d like to ask afterward, please get in touch with us.

Andrei Andon

analyst
#46

Hello, Massimo and James. This is Andrei Andon from Jefferies. Thanks a lot for taking my questions. I have two quick ones for you, please. First, in Germany, there's this law that was passed last week which means excise taxes are going to rise far more steeply over the next four years. How do you think that will impact combustibles and heated tobacco in Germany when it comes to volumes and pricing ability in 2027 and beyond? Then my second question: ZYN shipment growth in the U.S. was just over 4% year-on-year in Q3. That does seem fairly ahead of third-party scanner data, which appears to suggest volumes were down mid-single digits in Q3. Could that gap be explained by a restocking benefit, or do other factors come into play? Thank you.

Massimo Andolina

executive
#47

Many thanks, Andrei. I'll start with what you asked about Germany. We operate across a broad set of countries worldwide, as you're aware, and facing sudden, unusually large tax hikes isn't a new situation for us. If you look at what's happened lately, we've seen similar developments of even bigger scale during the last two years in Belgium and the Netherlands, in Poland two years ago, and more recently in India and Mexico; dealing with these kinds of events is genuinely something we're experienced at. On the German side, the government has introduced a tax pass-on that's larger than what we typically see—it falls somewhere between EUR 0.83 and EUR 0.88, from what I understand, taking effect January 1st. Andrei, I'd like to point out a few favorable aspects of this. The first and most important is that the gap versus HTU has been preserved, meaning HTU still enjoys a tax benefit compared with the tax on the underlying cigarette. The second thing worth highlighting: if there's any market where we're ideally placed to be highly competitive—even when taxes go up—it's Germany. Marlboro is the strongest brand we have there. In Germany, Marlboro's equity stands among the strongest we have anywhere globally, joined by a handful of other brands—L&M sits right behind it as the companion brand. Marlboro and the full portfolio have been rolled out effectively across many formats, including packs with very high stick counts, and also combined with last year's Marlboro Crafted launch. That launch has done extremely well, and it lets us compete across every price tier, which means we can compete with real strength. I have to say, is it something we welcome when the German government brings in a tax hike of that size? No, we don't, since we understand where that path leads. That pattern has shown up clearly for us in the U.K., and likewise in France, Belgium, and the Netherlands. Ultimately, this drives additional volume to illegal operators, and the government ends up collecting less tax revenue, while the legal industry can also see lower revenue at times. Still, if any company in Germany is positioned to compete effectively in that kind of environment, it is ours, given the portfolio we hold and how strong our brands are. At this stage, I'd say that as cigarette prices rise, yes, HTUs will rise as well, though to a smaller degree, because of the tax differential, and we will stay focused on growing IQOS in Germany, which, as I mentioned earlier, is posting double-digit IMS growth this year, and for us that matters enormously. I'll get to your question about ZYN growth. Andrei, may I ask you to clarify your question on ZYN growth once more, please.

Andrei Andon

analyst
#48

Uh-huh. That reported shipment figure — a bit more than +4% for U.S. volumes — does appear to be running ahead of the scanner data we've looked at, which would have pointed to something like a mid-single digit volume decline in Q3. So I was just wondering whether that gap comes from some restocking, or whether other factors are at play that would account for the difference.

Massimo Andolina

executive
#49

Well, all I can say is that this is the shipment data we have, and we're growing 4.2% in the quarter. And actually, something to keep in mind is that if you look at the comparison with the fact that in September last year we had the nicotine pouch promotion that landed in the month of September — we're actually taking out that unfavorable comparison, growing 13% in the quarter net of that comparison. That's perhaps the element you may want to bear in mind when reconciling your figures. The second thing I'd point out is that obviously in the quarter there's the rollout and pipelining and expanded distribution of our new variants and the flavors on the dry portfolio, plus the launch of the ULTRA variants. So over the course of the quarter, there was obviously an increase in distribution; we believe that for those variants, we're now fully covered on distribution. We're now building the 1 for 1.5 at 8, but those obviously contributed to our shipment growth in the quarter. Does that answer your question, Andrei?

Andrei Andon

analyst
#50

Yeah. Thank you very much.

Massimo Andolina

executive
#51

Thank you.

James Bushnell

executive
#52

Much appreciated. Apologies in case we didn’t get to everyone’s question. Kindly reach out to the Investor Relations team afterward. That wraps up today’s call. Thanks for being with us, and enjoy the rest of your day.

Operator

operator
#53

We appreciate everyone joining us for today's call. That brings the program to a close. You're welcome to disconnect at this point. Have a wonderful day, everybody.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Philip Morris International Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Philip Morris International Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Philip Morris International Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.